Journal
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
Volume 22, Issue 2, Pages 114-123Publisher
WILEY
DOI: 10.1002/jhbp.156
Keywords
Biliary cancers; Biomarkers; Gene fusions; Gene mutations; Liver cancers
Categories
Funding
- National Institutes of Health [R01DK069370, UH2TR000884]
Ask authors/readers for more resources
Intrahepatic cholangiocarcinomas (iCCA) are primary intrahepatic malignancies originating from biliary epithelia. While both hepatocellular cancer and iCCA can present as mass lesions within the liver, these cancers are distinct in their morphology, etiology, pathology, natural history and response to therapy. There is a need for accurate and sensitive molecular markers for the diagnosis of iCCA. Recent advances in elucidating molecular and genetic characteristics of iCCA offer the potential of molecular-based diagnosis of iCCA. Specific genetic mutations of IDH1/2, BAP1, p53, and KRAS, FGFR gene fusions and alterations in microRNA have all been described in iCCA. Although there are no accurate serum or biliary biomarkers currently available for diagnosis of iCCA, several potential candidates have been identified. Knowledge of specific genetic or molecular abnormalities offers potential for individualized approaches for the treatment of patients with iCCA in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available